Garry A. Neil
InvestorChief Executive Officer at Avalo Therapeutics
Find your path to Garry
20 people in our graph share verified history with Garry — schools, employers, funds. One of them is your warm intro.
Aaron KantoffunlockedGarry: together at Avalo Therapeutics
×11Garry: together at Avalo Therapeutics
About
CEO of Avalo since February 2022 with extensive experience in pharmaceutical R&D and corporate leadership. Previously served as Chief Scientific Officer at Aevi Genomic Medicine and held senior roles at Johnson & Johnson, including Corporate VP of Science & Technology, as well as positions at Merck KGaA, AstraZeneca, and leading academic research institutions.
Colleagues at Avalo Therapeutics
Aaron Kantoff
Board Member at Avalo Therapeutics
Aaron Kantoff
Managing Partner at Scion Life Sciences
Amy Conrad
Senior Events Manager at Volta Labs
Ashley Ivanowicz
Senior Vice President, Human Resources at Avalo Therapeutics
Chris Sullivan
Chief Financial Officer at Avalo Therapeutics
Colleen Matkowski
Senior Vice President, Global Regulatory Affairs and Quality Assurance at Avalo Therapeutics
Dino C. Miano
Senior Vice President, CMC and Technical Operations at Avalo Therapeutics
Garrett Lauderdale
Vice President at Idea of La Crosse
Frequently asked questions
- Who is Garry A. Neil?
- CEO of Avalo since February 2022 with extensive experience in pharmaceutical R&D and corporate leadership. Previously served as Chief Scientific Officer at Aevi Genomic Medicine and held senior roles at Johnson & Johnson, including Corporate VP of Science & Technology, as well as positions at Merck KGaA, AstraZeneca, and leading academic research institutions.
- Where does Garry A. Neil work?
- Garry A. Neil is Chief Executive Officer at Avalo Therapeutics.